manjaro glp 1 agonist Mounjaro: What You Should Know About the New Type 2 Diabetes Medicine Mounjaro (tirzepatide) for the Treatment

Weight loss compared to placebo was ~5% in RCTs

These may include: Nausea, vomiting or diarrhoea (most common early on) Constipation Fatigue Mild increases in heart rate (similar to changes seen with GLP-1 medicines) Side effects were more frequent at higher doses (8 mg and 12 mg), but still rated mild to moderate overall

Medicine (Baltimore) 98(28):e15959 Verma S, McGuire DK, Bain SC, Bhatt DL, Leiter LA, Mazer CD, Monk Fries T, Pratley RE, Rasmussen S, Vrazic H et al (2020) Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials

Viljoen, A

Indicator #3 The cost of Financialization: More Spent on Shareholders than R&D (FIGURE 3) Ratio of Spending on R&D vs Shareholder Enrichment for Leading Pharmaceutical Companies 2020-2024 The figure shows the ratio of total spending on R&D versus shareholder enrichment (stock buybacks plus shareholder dividends) for 15 peer companies during the five year period from 2020-2024